Clinical Outcomes of Rifaximin Combined with Probiotics in Patients with Functional Diarrhea A Prospective Cohort Study
This prospective cohort study suggests that combining rifaximin with probiotics may offer superior maintenance of improved stool consistency and reduced bowel frequency at one month compared to probiotics alone in adults with functional diarrhea, though these exploratory findings warrant confirmation through randomized controlled trials.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of people, the digestive system is a source of constant, unpredictable distress. Among the various conditions that disrupt daily life, functional diarrhea stands out as a chronic puzzle. Unlike infections caused by a specific germ or inflammation from a disease like Crohn's, this condition involves a gut that behaves erratically without a clear, visible cause. The hallmark is loose or watery stools that persist for weeks or months, often accompanied by a sudden, urgent need to use the restroom. While doctors often turn to probiotics—beneficial bacteria intended to restore balance to the gut's natural ecosystem—to help manage these symptoms, the results are frequently inconsistent. Some patients find relief, while others see no change at all. This uncertainty leaves many searching for a more reliable solution, leading researchers to investigate whether adding a specific type of antibiotic, one that stays in the gut and does not enter the bloodstream, could tip the scales toward recovery when paired with probiotics.
A team of researchers in China set out to explore this question by observing the real-world choices of patients suffering from this chronic condition. Between April 2022 and June 2024, they recruited adults who had been diagnosed with functional diarrhea according to strict medical criteria. Instead of randomly assigning treatments, the study allowed patients to choose their path after discussing options with their doctors. One group of patients opted for a combination therapy: a six-day course of the antibiotic rifaximin, taken twice daily, alongside a two-week regimen of two specific types of probiotics. The other group chose to take only the probiotics for the same two-week period. The researchers then tracked these patients at the end of their treatment and again one month later, looking closely at the consistency of their stools, how often they needed to go, and whether they felt a sense of urgency or incomplete emptying.
The study followed 121 patients who completed the full course of treatment and the subsequent follow-up. The results showed that both groups improved significantly over time. Patients who took only probiotics saw their stools become more formed and their bowel movements become less frequent, a clear sign that the beneficial bacteria were helping. However, the group that added the antibiotic to their probiotic regimen showed a distinct advantage in how long that improvement lasted. One month after treatment ended, the patients who had taken the combination therapy maintained better stool consistency than those who had taken probiotics alone. They also reported fewer daily bowel movements at that same one-month mark. While the antibiotic did not appear to offer a dramatic boost in the immediate days following treatment, its presence seemed to help the gut hold onto the benefits of the probiotics for a longer period.
Not every symptom responded differently between the two groups. Both sets of patients reported a significant reduction in the urgent need to defecate and the feeling of incomplete evacuation, but the data did not show that the antibiotic group improved more than the probiotic-only group for these specific issues. The researchers also looked at other common complaints, such as excessive gas, stomach rumbling, and mucus in the stool. They found that the combination therapy group had a lower risk of frequent flatulence one month after treatment compared to the other group, but the other symptoms did not show a clear difference between the two approaches. Throughout the study, no serious side effects were reported, suggesting that the combination of the antibiotic and the probiotics was safe for these patients to use.
The researchers were careful to note that their findings, while promising, come from an observational study where patients chose their own treatments rather than a randomized trial where a coin flip decides the group. This means that while the data suggests the combination therapy helps maintain improvements in stool consistency and frequency for a month after treatment, it is not yet definitive proof. The study did not include detailed testing of the gut bacteria to explain exactly why the antibiotic helped, so the mechanism remains a hypothesis rather than a confirmed fact. Nevertheless, the results offer a hopeful signal for those struggling with functional diarrhea, suggesting that a short course of a gut-specific antibiotic might help the benefits of probiotics last longer, providing a more stable path toward relief.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.